Search Results
You are looking at 1 - 1 of 1 items for
- Author: H Pisarek x
- Refine by access: All content x
Search for other papers by H Stępień in
Google Scholar
PubMed
Search for other papers by M Grochal in
Google Scholar
PubMed
Search for other papers by K W Zieliński in
Google Scholar
PubMed
Search for other papers by S Mucha in
Google Scholar
PubMed
Search for other papers by J Kunert-Radek in
Google Scholar
PubMed
Search for other papers by A Kulig in
Google Scholar
PubMed
Search for other papers by A Stawowy in
Google Scholar
PubMed
Search for other papers by H Pisarek in
Google Scholar
PubMed
Abstract
The process of angiogenesis occurs in many physiological states, but it is also essential for the growth of solid tumours and metastasis formation. An abnormal arterial vascularization has been shown in prolactin-secreting pituitary adenomas induced by prolonged treatment with oestrogens in Fischer 344 (F344) rats. It is thought that anti-angiogenic agents might be useful in therapy for these tumours.
Fumagillin and its analogue TNP-470 are known to inhibit endothelial cell proliferation selectively, but their effect on lactotroph cell secretory function and prolactinoma formation has not yet been described. The aim of the present study was to examine the effects of fumagillin and TNP-470 on prolactin secretion, and morphological and vascular changes within the anterior pituitary in long-term oestrogen-treated male F344 rats in vivo and in vitro. As expected, 7 weeks after s.c. implantation of Silastic tubes containing 10 mg diethylstilboestrol (DES), a very high rise in serum prolactin levels was found. Both angiogenesis inhibitors injected s.c. at doses of 10 mg/kg body weight for 24 days attenuated the stimulatory effect of DES on prolactin production and release. They also diminished prolactin cell density and inhibited cell proliferation expressed as the number of anterior pituitary cells labelled with bromodeoxyuridine (BrdU), but the effect of TNP-470 was minor compared with fumagillin. Both angioinhibitors suppressed neovascularization within the anterior pituitary with similar potency but, on the other hand, they did not affect DES-induced increases in prolactin secretion from cultured rat pituitary cells and cell proliferation in vitro.
In conclusion, our results provide strong evidence for the anti-tumour and anti-prolactin activity of angiogenesis inhibitors in the experimentally oestrogen-induced pituitary adenoma; this might be mediated indirectly through the inhibition of angiogenesis.
Journal of Endocrinology (1996) 150, 99–106